Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRTX-1001 in drug-resistant bilateral temporal lobe epilepsy
NCT06422923Phase 2Recruiting
- Sponsor
- Neurona Therapeutics
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of NRTX-1001 in temporal lobe epilepsy (TLE), sponsored by Neurona Therapeutics. Started Nov 2024; status: recruiting.
02
Drugs
NRTX-1001
03
Conditions
temporal lobe epilepsy (TLE)
Beyond the preview
Go deeper on NCT06422923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422923.